Hagerman, Randi J.
Berry-Kravis, Elizabeth
Hazlett, Heather Cody
Bailey, Donald B. Jr
Moine, Herve
Kooy, R. Frank
Tassone, Flora
Gantois, Ilse
Sonenberg, Nahum
Mandel, Jean Louis
Hagerman, Paul J.
Article History
First Online: 29 September 2017
Competing interests
: R.J.H. has received funding from Novartis, Roche, Alcobra, Neuren and Marinus for clinical trials in FXS and has consulted with Zynerba for clinical trials in FXS. E.B.-K. has received funding from Novartis, Roche, Alcobra, Neuren, Cydan, Fulcrum, GW, Marinus, Edison and Neurotrope Pharmaceuticals to consult on trial design and development strategies and/or conduct clinical trials in FXS, and from Asuragen Inc. to develop testing standards for <i>FMR1</i> testing. D.B.B. received funding from The John Merck Fund to plan a fragile X newborn screening study. R.F.K. has received logistic support and ganaxolone treatment funding from Marinus Pharmaceuticals to conduct a clinical trial in FXS. F.T. has received funding for molecular studies in FXS from Asuragen. All other authors declare no competing interests.